Video: Global Laboratory Capabilities

As part of our integrated site infrastructure, Velocity has established specialized laboratory and diagnostic capabilities. This includes purpose-built, CLIA-certified lab facilities at all dedicated sites, as well as in-network PBMC processing at 30+ Velocity locations across the U.S. and Europe. As Nick Spittal, Chief Operations Officer, explains in this video, Velocity is also using these … Read more

Therapeutic Area Thursday Webinars: Enhancing Specialty Trial Support Through Expert Knowledge Sharing

How can one specialist’s deep therapeutic expertise transform the way 90+ sites worldwide operate and engage patients? In the past month, Nadege Gunn, MD, CPI, gave an insightful internal presentation on MASH. A renowned expert in gastroenterology and hepatology, Dr. Gunn shared her invaluable expertise, drawing from her extensive experience in bridging clinical trials with … Read more

Video: Principal Investigator Experience and Engagement

About half of Principal Investigators (PIs) conduct only a single study in their career. This high turnover rate results in significant inefficiencies for Sponsors and CROs, particularly when it comes to finding reliable PIs capable of delivering high-quality trial conduct and enrollment in specialized research areas.

Velocity developed the innovative Principal Investigator Onboarding and Training (PIVOT) Program to address the pressing issue of “one-and-done” PIs in clinical research. This strategic initiative equips new PIs with comprehensive knowledge, tools, infrastructure, and mentorship opportunities.

The PIVOT Program:

  • Elevates PI engagement, performance, and retention through a novel curriculum
  • Combines industry leading training content, hands-on experiences, and mentorship
  • Specific training tracks for full-time PIs and specialist PIs with embedded operations

Learn more at

Velocity Joins the IQVIA Connected Research Community in Europe

Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is to share ideas, lessons-learned, challenges, and innovations across our sites and … Read more

Video: Community Engagement

To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive change. Our focus is on managing what we can effectively control … Read more

Julio Rosenstock, MD, FACE, Co-Authored an Article Published in Cardiovascular Diabetology

Julio Rosenstock, MD, FACE, is an author of an article published yesterday in Cardiovascular Diabetology. Using baseline characteristics of study participants from an ongoing trial, researchers identified clinical characteristics of individuals with type 2 diabetes and features of stage B heart failure that may help clarify the diagnosis of diabetic cardiomyopathy (DbCM) in clinical practice. Read … Read more

Video: Environmental Governance

As Nicholas Campbell explains, good business can also be good for the environment. As Velocity improves lives by accelerating the development of new therapies, we can also build a healthier tomorrow by conducting trials in a sustainable way. How can Velocity deliver more efficient trials? Enhanced site enrollment forecasting to minimize overages, alongside reduced investigational product distribution … Read more

Julio Rosenstock, MD, FACE, Lead Author Published in OUP Endocrine Reviews Article

Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a … Read more

Video: Demand and Delivery

Watch Christy Godwin and Laura Falcone discuss Velocity’s unique ‘Demand and Delivery’ approach. Christy and Laura work in unison to ensure full alignment among what Sponsors and CROs demand, and the quality, performance, and patient experiences Velocity delivers. In this video, they delve into: The importance of understanding goals and translating them into actionable strategies … Read more